Recce Pharmaceuticals Ltd
RECEF · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $8 | $7 | $4 | $3 |
| % Growth | 9.6% | 56.9% | 41.5% | – |
| Cost of Goods Sold | $10 | $7 | $0 | $0 |
| Gross Profit | -$3 | -$0 | $4 | $3 |
| % Margin | -39.1% | -5.4% | 95% | 93.9% |
| R&D Expenses | $10 | $0 | $7 | $6 |
| G&A Expenses | $8 | $6 | $4 | $2 |
| SG&A Expenses | $10 | $7 | $5 | $3 |
| Sales & Mktg Exp. | $1 | $1 | $1 | $1 |
| Other Operating Expenses | $0 | $0 | $4 | $2 |
| Operating Expenses | $20 | $14 | $17 | $14 |
| Operating Income | -$23 | -$22 | -$17 | -$14 |
| % Margin | -304.7% | -321.9% | -396.9% | -458.7% |
| Other Income/Exp. Net | $1 | -$1 | $4 | -$4 |
| Pre-Tax Income | -$21 | -$23 | -$17 | -$14 |
| Tax Expense | $0 | -$5 | -$4 | -$3 |
| Net Income | -$21 | -$18 | -$13 | -$11 |
| % Margin | -285.4% | -257.8% | -299.6% | -356.1% |
| EPS | -0.09 | -0.1 | -0.074 | -0.063 |
| % Growth | 9.3% | -34% | -19% | – |
| EPS Diluted | -0.09 | -0.1 | -0.074 | -0.063 |
| Weighted Avg Shares Out | 237 | 177 | 176 | 176 |
| Weighted Avg Shares Out Dil | 237 | 177 | 176 | 176 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $1 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$20 | -$21 | -$17 | -$11 |
| % Margin | -270.8% | -311.7% | -389.2% | -350% |